Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.

15 brokers have issued 12 month price objectives for Vertex Pharmaceuticals' stock. Their VRTX share price forecasts range from $280.00 to $374.00. On average, they expect the company's share price to reach $322.79 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.

Vertex Pharmaceuticals' stock was trading at $288.78 on January 1st, 2023. Since then, VRTX shares have increased by 6.3% and is now trading at $307.07.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our VRTX earnings forecast.

Vertex Pharmaceuticals will be holding an earnings conference call on Tuesday, February 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Tuesday, November, 2nd. The pharmaceutical company reported $3.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.82. The pharmaceutical company had revenue of $1.98 billion for the quarter, compared to analyst estimates of $1.85 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 29.65% and a net margin of 37.62%. During the same quarter in the prior year, the company posted $2.36 EPS.
Read the conference call transcript.

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.33%), Assenagon Asset Management S.A. (0.29%), Mayflower Financial Advisors LLC (0.28%), Vaughan Nelson Investment Management L.P. (0.19%), New York State Common Retirement Fund (0.18%) and Natixis Advisors L.P. (0.18%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRTX stock can currently be purchased for approximately $307.07.

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $78.82 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.68 on an earnings per share basis.

The company employs 3,900 workers across the globe.

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.